Which has stronger valuation & earnings, VALN or CLLS?

Cellectis has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.76 -$130.33M -$2.11 N/A Cellectis $56.58M 2.54 -$67.59M -$0.65 N/A

Is VALN or CLLS more profitable?

Cellectis has a net margin of -102.34% compared to Valneva's net margin of -110.33%. Cellectis' return on equity of -94.19% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% Cellectis -102.34% -94.19% -21.34%

Does the media prefer VALN or CLLS?

In the previous week, Cellectis had 6 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Cellectis and 1 mentions for Valneva. Cellectis' average media sentiment score of 0.28 beat Valneva's score of 0.00 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CLLS or CBIO?

In the previous week, Cellectis had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Cellectis and 2 mentions for Crescent Biopharma. Cellectis' average media sentiment score of 0.28 beat Crescent Biopharma's score of 0.25 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLLS or ALLO?

In the previous week, Cellectis had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Cellectis and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.84 beat Cellectis' score of 0.28 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend VECT or CLLS?

Cellectis has a consensus target price of $5.46, indicating a potential upside of 281.82%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than VectivBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cellectis 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.29

Which has stronger earnings & valuation, VECT or CLLS?

VectivBio has higher earnings, but lower revenue than Cellectis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VectivBio N/A N/A N/A N/A N/A Cellectis $56.58M 2.54 -$67.59M -$0.65 N/A

Is VECT or CLLS more profitable?

VectivBio has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. VectivBio's return on equity of 0.00% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets VectivBio N/A N/A N/A Cellectis -102.34% -94.19% -21.34%

Which has higher valuation and earnings, PROK or CLLS?

Cellectis has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 584.26 -$68.99M -$0.55 N/A Cellectis $56.58M 2.54 -$67.59M -$0.65 N/A

Is PROK or CLLS more profitable?

Cellectis has a net margin of -102.34% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -10,288.39% N/A -27.39% Cellectis -102.34% -94.19% -21.34%

Does the media refer more to PROK or CLLS?

In the previous week, Cellectis had 4 more articles in the media than ProKidney. MarketBeat recorded 7 mentions for Cellectis and 3 mentions for ProKidney. ProKidney's average media sentiment score of 0.55 beat Cellectis' score of 0.28 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Cellectis (CLLS) Competitors

$1.43 +0.03 (+2.14%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.39 -0.04 (-2.73%)

As of 10/2/2026 07:30 PM Eastern

Compare

CLLS vs. VALN, CBIO, ALLO, VECT, and PROK

Should you buy Cellectis stock or one of its competitors? Cellectis's main competitors and comparable companies include Valneva (VALN), Crescent Biopharma (CBIO), Allogene Therapeutics (ALLO), VectivBio (VECT), and ProKidney (PROK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellectis compare to Valneva?

Valneva (NASDAQ:VALN) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Cellectis had 6 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Cellectis and 1 mentions for Valneva. Cellectis' average media sentiment score of 0.28 beat Valneva's score of 0.00 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Valneva currently has a consensus price target of $9.30, suggesting a potential upside of 62.02%. Cellectis has a consensus price target of $5.46, suggesting a potential upside of 281.82%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cellectis	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.29

11.4% of Valneva shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valneva has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Cellectis has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Cellectis has a net margin of -102.34% compared to Valneva's net margin of -110.33%. Cellectis' return on equity of -94.19% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Cellectis	-102.34%	-94.19%	-21.34%

Cellectis has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.76	-$130.33M	-$2.11	N/A
Cellectis	$56.58M	2.54	-$67.59M	-$0.65	N/A

Summary

Cellectis beats Valneva on 15 of the 17 factors compared between the two stocks.

How does Cellectis compare to Crescent Biopharma?

Cellectis (NASDAQ:CLLS) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Crescent Biopharma has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Cellectis' return on equity of -94.19% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Crescent Biopharma	N/A	-101.50%	-86.86%

Cellectis has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Cellectis presently has a consensus price target of $5.46, suggesting a potential upside of 281.82%. Crescent Biopharma has a consensus price target of $29.60, suggesting a potential upside of 106.70%. Given Cellectis' higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.29
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Cellectis had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Cellectis and 2 mentions for Crescent Biopharma. Cellectis' average media sentiment score of 0.28 beat Crescent Biopharma's score of 0.25 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cellectis has higher revenue and earnings than Crescent Biopharma. Cellectis is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$56.58M	2.54	-$67.59M	-$0.65	N/A
Crescent Biopharma	$10.84M	49.06	-$153.94M	-$6.72	N/A

Summary

Cellectis beats Crescent Biopharma on 9 of the 16 factors compared between the two stocks.

How does Cellectis compare to Allogene Therapeutics?

Cellectis (NASDAQ:CLLS) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

In the previous week, Cellectis had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Cellectis and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.84 beat Cellectis' score of 0.28 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cellectis has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectis has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$56.58M	2.54	-$67.59M	-$0.65	N/A
Allogene Therapeutics	$20K	25,911.75	-$190.89M	-$0.67	N/A

Cellectis currently has a consensus target price of $5.46, indicating a potential upside of 281.82%. Allogene Therapeutics has a consensus target price of $8.30, indicating a potential upside of 453.33%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.29
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Allogene Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Allogene Therapeutics' return on equity of -50.04% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Summary

Allogene Therapeutics beats Cellectis on 9 of the 17 factors compared between the two stocks.

How does Cellectis compare to VectivBio?

VectivBio (NASDAQ:VECT) and Cellectis (NASDAQ:CLLS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

VectivBio has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. VectivBio's return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Cellectis	-102.34%	-94.19%	-21.34%

63.9% of Cellectis shares are held by institutional investors. 9.7% of VectivBio shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cellectis has a consensus target price of $5.46, indicating a potential upside of 281.82%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cellectis	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.29

In the previous week, Cellectis had 7 more articles in the media than VectivBio. MarketBeat recorded 7 mentions for Cellectis and 0 mentions for VectivBio. Cellectis' average media sentiment score of 0.28 beat VectivBio's score of 0.00 indicating that Cellectis is being referred to more favorably in the news media.

Company	Overall Sentiment
VectivBio	Neutral
Cellectis	Neutral

VectivBio has higher earnings, but lower revenue than Cellectis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	N/A	N/A	N/A	N/A	N/A
Cellectis	$56.58M	2.54	-$67.59M	-$0.65	N/A

Summary

Cellectis beats VectivBio on 9 of the 12 factors compared between the two stocks.

How does Cellectis compare to ProKidney?

ProKidney (NASDAQ:PROK) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Cellectis has a net margin of -102.34% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Cellectis	-102.34%	-94.19%	-21.34%

51.6% of ProKidney shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ProKidney presently has a consensus target price of $12.00, suggesting a potential upside of 597.67%. Cellectis has a consensus target price of $5.46, suggesting a potential upside of 281.82%. Given ProKidney's stronger consensus rating and higher probable upside, equities analysts clearly believe ProKidney is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cellectis	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.29

In the previous week, Cellectis had 4 more articles in the media than ProKidney. MarketBeat recorded 7 mentions for Cellectis and 3 mentions for ProKidney. ProKidney's average media sentiment score of 0.55 beat Cellectis' score of 0.28 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cellectis has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	584.26	-$68.99M	-$0.55	N/A
Cellectis	$56.58M	2.54	-$67.59M	-$0.65	N/A

ProKidney has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Cellectis has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market.

Summary

Cellectis beats ProKidney on 9 of the 16 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$140.48M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-2.20	13.06	275.68	26.04
Price / Sales	2.54	1,373.91	658.18	100.99
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	1.88	16.63	10.93	6.31
Net Income	-$67.59M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-2.72%	-2.99%	-2.01%	-1.66%
1 Month Performance	-56.93%	-10.60%	-6.15%	-4.50%
1 Year Performance	-59.14%	19.44%	7.44%	2.06%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	3.2225 of 5 stars	$1.43 +2.1%	$5.46 +281.8%	-58.2%	$140.48M	$56.58M	N/A	229	Short Interest Increase Gap Up
VALN Valneva	2.0753 of 5 stars	$6.65 +0.5%	$9.30 +39.8%	-50.0%	$630.92M	$197.56M	N/A	674
CBIO Crescent Biopharma	2.7506 of 5 stars	$16.30 +0.3%	$29.60 +81.6%	+19.0%	$605.01M	$10.84M	N/A	44
ALLO Allogene Therapeutics	2.208 of 5 stars	$1.72 +1.5%	$8.30 +384.0%	+16.3%	$592.52M	$20K	N/A	152	Positive News
VECT VectivBio	N/A	$16.85 flat	N/A	N/A	$573.24M	$27.34M	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors